Peptide vaccine-treated, long-term surviving cancer patients harbor self-renewing tumor-specific CD8⁺ T cells.

ABSTRACT: The behaviors and fates of immune cells in cancer patients, such as dysfunction and stem-like states leading to memory formation in T cells, are in intense focus of investigation. Here we show, by post hoc analysis of peripheral blood lymphocytes of hepatocellular carcinoma patients previously undergoing vaccination with tumour-associated antigen-derived peptides in our clinical trials (registration numbers UMIN000003511, UMIN000004540, UMIN000005677, UMIN000003514 and UMIN000005678), that induced peptide-specific T cell responses may persist beyond 10 years following vaccination. Tracking TCR clonotypes at the single cell level reveals in two patients that peptide-specific long-lasting CD8⁺ T cells acquire an effector memory phenotype that associates with cell cycle-related gen

SUBMITTER: Mizukoshi E 

PROVIDER: S-EPMC9166698 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature